Is Amycretin Approved? FDA Status and Likely Launch Timeline (2026)
No. Amycretin is still a Phase 3 program. It is one of Novo's most important next-wave assets, but it is not yet an approved commercial obesity drug.
Current stage
Phase 3
Approval read
Not yet approved for broad obesity use.
Likely window
2027 to 2028 is the realistic window if development continues smoothly.
Next step
Finish Phase 3 and prove that the amylin angle adds enough real-world value to matter commercially.
Direct answer
No. Amycretin is still a Phase 3 program. It is one of Novo's most important next-wave assets, but it is not yet an approved commercial obesity drug.
Status facts for search and AI answers
What this Amycretin (Zenagamtide) status page answers
Compound
Amycretin (Zenagamtide)
Amycretin (Zenagamtide) is tracked as a GLP-1/Amylin program from Novo Nordisk.
Approval read
Not yet approved for broad obesity use.
No. Amycretin is still a Phase 3 program. It is one of Novo's most important next-wave assets, but it is not yet an approved commercial obesity drug.
Likely window
2027 to 2028 is the realistic window if development continues smoothly.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Finish Phase 3 and prove that the amylin angle adds enough real-world value to matter commercially.
This is the milestone most likely to change the page's answer.
Decision path
What does Amycretin (Zenagamtide)'s status mean for access?
Amycretin (Zenagamtide)'s approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- Amycretin (Zenagamtide)
- Stage
- Phase 3
- Approval read
- Not yet approved for broad obesity use.
- Window
- 2027 to 2028 is the realistic window if development continues smoothly.
Step 1
Classify availability
Phase 3 GLP-1/amylin program with high strategic importance inside Novo's next-wave portfolio.
Read compound pageStep 2
Watch required milestone
Finish Phase 3 and prove that the amylin angle adds enough real-world value to matter commercially.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 3 GLP-1/amylin program with high strategic importance inside Novo's next-wave portfolio.
Amycretin matters because it is part of Novo's attempt to build a second act beyond classic GLP-1 framing.
What needs to happen next
Finish Phase 3 and prove that the amylin angle adds enough real-world value to matter commercially.
What FormBlends is watching
- Whether the data supports a cleaner tolerability or body-composition story than standard incretin expectations
- How Novo positions amycretin relative to CagriSema
- Whether clinicians start to see amylin as more than portfolio decoration
What could delay the timeline
- Internal portfolio crowding with other Novo assets
- A weaker-than-expected differentiation story
- Launch sequencing that favors nearer-term products first